Clinical Trial Detail

NCT ID NCT03777982
Title A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate cancer

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.